LIGUORI, CLAUDIO
 Distribuzione geografica
Continente #
NA - Nord America 12.076
EU - Europa 1.222
AS - Asia 877
SA - Sud America 13
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 3
Totale 14.202
Nazione #
US - Stati Uniti d'America 12.047
SG - Singapore 531
IE - Irlanda 286
IT - Italia 271
CN - Cina 172
RU - Federazione Russa 170
DE - Germania 124
KR - Corea 123
GB - Regno Unito 86
UA - Ucraina 84
FR - Francia 40
FI - Finlandia 38
SE - Svezia 38
CA - Canada 26
CZ - Repubblica Ceca 25
NL - Olanda 19
BE - Belgio 14
IN - India 14
BR - Brasile 7
CH - Svizzera 6
JP - Giappone 6
PL - Polonia 6
AU - Australia 5
HK - Hong Kong 5
DK - Danimarca 4
EU - Europa 4
PH - Filippine 4
CL - Cile 3
HU - Ungheria 3
MX - Messico 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
EG - Egitto 2
GR - Grecia 2
IR - Iran 2
KG - Kirghizistan 2
LK - Sri Lanka 2
RO - Romania 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AT - Austria 1
BD - Bangladesh 1
BG - Bulgaria 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
MK - Macedonia 1
MY - Malesia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
SA - Arabia Saudita 1
SI - Slovenia 1
TR - Turchia 1
TW - Taiwan 1
UZ - Uzbekistan 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 14.202
Città #
Wilmington 3.425
Houston 3.114
Woodbridge 1.695
Fairfield 645
Singapore 467
Chandler 460
Ashburn 357
Cambridge 259
Seattle 257
Dublin 244
Ann Arbor 182
Medford 180
Santa Clara 136
New York 115
Rome 114
Lawrence 86
Beijing 85
Dearborn 75
San Diego 61
Menlo Park 50
Moscow 34
Seoul 30
Jacksonville 29
Munich 26
London 25
Redwood City 25
Brno 24
Milan 23
Boardman 22
Norwalk 22
Helsinki 21
Durham 19
Toronto 19
Nanjing 16
Kilburn 15
Brussels 14
Philadelphia 14
Zhengzhou 12
Pune 11
San Jose 11
Creede 10
Palo Alto 10
Amsterdam 9
Council Bluffs 9
Shanghai 9
Atlanta 7
San Francisco 7
Bologna 6
Garden City 6
Los Angeles 6
Mountain View 6
Phoenix 6
Wuhan 6
Changsha 5
Kunming 5
Lappeenranta 5
Reggio Calabria 5
Shenzhen 5
The Dalles 5
Verona 5
Washington 5
Hefei 4
Huskvarna 4
Palermo 4
São Paulo 4
Budapest 3
Chengdu 3
Columbus 3
Esslingen am Neckar 3
Hounslow 3
Naples 3
Nashville 3
Redmond 3
Saint Petersburg 3
Solofra 3
Sutton Coldfield 3
Tokyo 3
Veracruz 3
Walton on Thames 3
Warsaw 3
Aigáleo 2
Alderley Edge 2
Apeldoorn 2
Augusta 2
Bangkok 2
Capranica 2
Casalecchio di Reno 2
Chicago 2
College Station 2
Colombo 2
Como 2
Desio 2
Doganella 2
Enfield 2
Ergolding 2
Falkenstein 2
Falls Church 2
Frankfurt am Main 2
Gatchina 2
Genoa 2
Totale 12.657
Nome #
Chronic dopaminergic treatment in restless legs syndrome: Does it affect the autonomic nervous system? 452
Obstructive sleep apnoea as a risk factor for osteopenia and osteoporosis in the male population: further data and comments 448
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 433
Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease 410
Effective treatment of nocturnal frontal lobe epilepsy with lacosamide: a report of two cases 405
Physical activity contradictorily affects bone mineral density in obstructive sleep apnea patients at different ages 393
Catecholamine-based treatment in AD patients: expectations and delusions 366
Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time 362
Does continuous positive airway pressure treatment affect autonomic nervous system in patients with severe obstructive sleep apnea? 342
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 339
Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsy: Further data 338
When cognitive decline and depression coexist in the elderly: CSF biomarkers analysis can differentiate Alzheimer's disease from late-life depression 330
Nocturnal frontal lobe epilepsy with paroxysmal arousals due to CHRNA2 loss of function 326
Obstructive sleep apnoea and bone health 323
Commentary: Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease 322
Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study 315
Daytime autonomic activity in idiopathic rapid eye movement sleep behavior disorder: a preliminary study 315
Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity 290
Continuous positive airway pressure treatment may improve optic nerve function in obstructive sleep apnea: An electrophysiological study 267
Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson’s disease 263
Low Serum 25(OH)D Levels in Parkinson ’s Disease; a Non Specific Marker of Neurodegeneration? 259
Sleep apnoeas may represent a reversible risk factor for amyloid-β pathology 252
Does fatigue in Parkinson’s disease correlate with autonomic nervous system dysfunction? 249
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study 245
Comparative Sleep Disturbances in Myotonic Dystrophy Types 1 and 2 240
Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study 227
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients 215
Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course 194
Heart rate variability in untreated newly diagnosed temporal lobe epilepsy: Evidence for ictal sympathetic dysregulation 193
Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk? 189
CSF levels of the endocannabinoid anandamide are reduced in patients with untreated narcolepsy type 1: a pilot study 189
Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimer's Disease Patients Showing Neuropsychiatric Symptoms 187
Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study 186
Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine 182
Postural and vestibular changes related to CPAP treatment in moderate-to-severe OSA patients: a 12-month longitudinal study 170
CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD 166
Depressive and anxiety symptoms in patients with SARS-CoV2 infection 165
Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid 157
Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer’s disease 150
Seasonality of restless legs syndrome: symptom variability in winter and summer times 150
Complement system dysregulation in patients affected by Idiopathic Generalized Epilepsy and the effect of antiepileptic treatment 143
Sleep-Wake Cycle in Alzheimer's Disease Is Associated with Tau Pathology and Orexin Dysregulation 137
Pitolisant for treating narcolepsy comorbid with Parkinson's disease 131
Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis 121
Laterality of Auditory Dysfunction in Parkinson's Disease 121
Obstructive sleep apnea is associated with early but possibly modifiable Alzheimer's disease biomarkers changes 121
Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection 114
Lateralization of cochlear dysfunction as a specific biomarker of Parkinson’s disease 107
New revolution in the assessment of cerebrospinal fluid orexin-A: Enzyme-linked immunosorbent assay! 104
The Italian version of the “frailty index” based on deficits in health: a validation study 86
Chronic obstructive pulmonary disease and long-term mortality in elderly subjects with chronic heart failure 83
Acute care hospital at different levels of intensity: the role of Geriatrician 77
18F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment 77
Is it time to consider obstructive sleep apnea syndrome a risk factor for Alzheimer's disease? 75
Increased noradrenaline as an additional cerebrospinal fluid biomarker in PSP-like parkinsonism 74
The reverse metabolic syndrome in the elderly: Is it a “catabolic” syndrome? 72
Biomarkers of cerebral glucose metabolism and neurodegeneration in Parkinson's disease: a cerebrospinal fluid-based study 72
Sarcopenia: Assessment of disease burden and strategies to improve outcomes 69
Multidimensional frailty evaluation in elderly outpatients with chronic heart failure: A prospective study 69
The actigraphic documentation of circadian sleep-wake rhythm dysregulation in myotonic dystrophy type 1 67
Physical Activity Scale for the Elderly (PASE) Score Is Related to Sarcopenia in Noninstitutionalized Older Adults 64
Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1 57
Risk of Malnutrition Evaluated by Mini Nutritional Assessment and Sarcopenia in Noninstitutionalized Elderly People 56
Dyspnea perception and neurological symptoms in non-severe COVID-19 patients 54
Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy? 54
Autonomic functions in focal epilepsy: A comparison between lacosamide and carbamazepine monotherapy 53
Correction to: Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course 53
Autonomic symptoms, cardiovascular and sudomotor evaluation in de novo type 1 narcolepsy 53
Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect. 52
Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. 52
Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy 52
COVID-19: dealing with a potential risk factor for chronic neurological disorders 49
Depressive symptoms in patients with epilepsy and clinically associated features in a single tertiary center 45
Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations 44
Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy 44
Sleep problems affect quality of life in Parkinson's disease along disease progression. 43
Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort 41
Physical activity changes and correlate effects in patients with Parkinson's disease during COVID-19 lockdown 41
Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study 40
Obstructive sleep apnea syndrome and Alzheimer's disease pathology: may continuous positive airway pressure treatment delay cognitive deterioration? 39
Sleep-wake cycle dysregulation in idiopathic REM sleep behaviour disorder 38
Assessment of Psychometric Characteristics of Parkinson’s Disease Sleep Scale 2 and Analysis of a Cut-Off Score for Detecting Insomnia in Italian Patients with Parkinson’s Disease: A Validation Study 38
Nocturnal hypoxia and sleep fragmentation may drive neurodegenerative processes: the compared effects of obstructive sleep apnea syndrome and periodic limb movement disorder on Alzheimer's disease biomarkers 35
STN-DBS Induces Acute Changes in β-Band Cortical Functional Connectivity in Patients with Parkinson's Disease 34
Perampanel may represent an effective treatment for the prevention of migraine comorbid with epilepsy 33
Obstructive sleep apnea, palatal morphology, and aortic dilatation in marfan syndrome growing subjects: A retrospective study 32
Sleep and wake impairment in patients with SARS-CoV2 infection 31
Subthalamic nucleus deep brain stimulation on motor-symptoms of Parkinson's disease: Focus on neurochemistry. 30
Neuropsychiatric, neuropsychological, and neuroimaging features in isolated REM sleep behavior disorder: The importance of MCI 29
Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson’s Disease 28
Parkinson's disease motor progression in relation to the timing of REM sleep behavior disorder presentation: an exploratory retrospective study 28
Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates 26
Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up 26
Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder 23
Cerebrospinal-fluid biomarkers for predicting phenoconversion in patients with isolated rapid-eye movement sleep behavior disorder 22
Periodic sharp wave complexes identify a distinctive phenotype in Creutzfeldt-Jacob disease. 22
Exploring the Association Linking Head Position and Sleep Architecture to Motor Impairment in Parkinson’s Disease: An Exploratory Study 21
More than sleep and wake disturbances: An actigraphic study showing the sleep-wake pattern dysregulation in epilepsy 21
Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study 20
Both Motor and Non-Motor Fluctuations Matter in the Clinical Management of Patients with Parkinson’s Disease: An Exploratory Study 19
Totale 14.466
Categoria #
all - tutte 45.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.730


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.977 0 0 0 0 276 315 296 471 521 421 336 341
2020/20213.249 373 349 367 358 342 387 388 298 59 143 123 62
2021/20221.112 41 65 46 31 18 46 219 25 51 81 72 417
2022/20231.235 142 118 49 132 109 254 106 98 115 20 51 41
2023/2024658 73 13 37 20 60 178 36 107 13 21 8 92
2024/20251.167 119 536 269 158 85 0 0 0 0 0 0 0
Totale 14.655